Ribonucleotide reductase inhibitors are a family of anti-cancer drugs that interfere with the growth of tumor cells by blocking the formation of deoxyribonucleotides (building blocks of DNA ).
Examples include:
See also
References
^ Zahedi Avval F, Berndt C, Pramanik A, Holmgren A (January 2009). "Mechanism of inhibition of ribonucleotide reductase with motexafin gadolinium (MGd)". Biochem. Biophys. Res. Commun . 379 (3): 775– 9. doi :10.1016/j.bbrc.2008.12.128 . PMID 19121624 . ^ Mayhew CN, Phillips JD, Cibull ML, Elford HL, Gallicchio VS (September 2002). "Short-term treatment with novel ribonucleotide reductase inhibitors Trimidox and Didox reverses late-stage murine retrovirus-induced lymphoproliferative disease with less bone marrow toxicity than hydroxyurea" . Antivir. Chem. Chemother . 13 (5): 305– 14. doi :10.1177/095632020201300506 PMID 12630679 . ^ Tsimberidou AM, Alvarado Y, Giles FJ (August 2002). "Evolving role of ribonucleoside reductase inhibitors in hematologic malignancies". Expert Rev Anticancer Ther . 2 (4): 437– 48. doi :10.1586/14737140.2.4.437 . PMID 12647987 . S2CID 30047759 . ^ Bernstein LR (1998). "Mechanisms of therapeutic activity for gallium" (PDF) . Pharmacol. Rev . 50 (4): 665– 682. PMID 9860806 . ^ Bitonti, A. J.; Dumont, J. A.; Bush, T. L.; Cashman, E. A.; Cross-Doersen, D. E.; Wright, P. S.; Matthews, D. P.; McCarthy, J. R.; Kaplan, D. A. (15 March 1994). "Regression of human breast tumor xenografts in response to (E)-2'-deoxy-2'-(fluoromethylene)cytidine, an inhibitor of ribonucleoside diphosphate reductase" . Cancer Research . 54 (6): 1485– 1490. PMID 8137252 . ^ "Tezacitabine monohydrate" .
External links
public domain material from Dictionary of Cancer Terms U.S. National Cancer Institute .
